Vaccinal strategies in response to new epidemiological challenges in 2010. Reasonable hope for a "B" vaccine;Méningocoques et vaccins méningococciques: Face aux nouvelles situations épldémiologlques: Les stratégies vaccinales en 2010, les espoirs raisonnables pour le vaccin «B»

Medecine Tropicale

Volumn 70, Issue 4, 2010, Pages 325-332

  Nicolas, P ^a  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

Author keywords

Conjugated vaccine; Meningcoccal; Meningococcus; Neisseria meningitides; Polysaccharide vaccine; Vaccine

Indexed keywords

MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PORIN A; PROTEIN; VACCINE;

AFRICA; EPIDEMIC; EPIDEMIC MENINGITIS; HOPE; MEMBRANE VESICLE; MENINGITIS; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEW ZEALAND; NORWAY; OUTER MEMBRANE; UNITED KINGDOM; ARTICLE; HEALTH; HUMAN; IMMUNOLOGY;

NEISSERIA MENINGITIDIS; OAT MOSAIC VIRUS;

HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; VACCINES, CONJUGATE; WORLD HEALTH;

EID: 84859395999     PISSN: 0025682X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Nicolas P, Debonne JM. Infections à méningocoques. EMC8-O13-A-10 Pédiatrie/Maladies Infectieuses 4-250-A-30, 2002. 23p.
2. Parent Du Chstelei I, Taha MK, Lepoulre A, Ala-Eddi Deghmane, Maine C, Lévy-Brilhl D. Les infections invasives à méningocoques en France en 2008. BEH 2009;46-47-. 489-93.
3. Bovre K, Gedde-Dahl TW. Epidemiological patterns of meningococcal disease in Norway 1975-1979. NIPHAnn 1980;3:9-22.
4. Lystad A, Aasen S. The epidemiology of meningococcal disease in Norway 1975-91. NIPH Ann 1991;14;57-66.
5. Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified a strain with phenotype B: 4PI.4. J Infect Dis 1998;177:497-500. (Pubitemid 28063785)
6. Lapeyssonnie L. La méningite cérébro-spinale en Afrique. Bull World Health Organ 1963;28 1-114.
7. Nicolas P. Douze années d'épidémies de méningite à méningocoques en Afrique. La Lettre de la société de Médecine des Voyages 2000;1:3-4.
8. Nicolas P. Epidémie de méningite à méningocoques du sérogroupe W135 en 2000 et 2001. Med Trop 2001;61:259-61. (Pubitemid 33701042)
9. Djibo S, Nicolas P, Alonso JM, Djibo A, Couret D, Riou JY, Chippaux JP. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 2003;8:1118-23. (Pubitemid 38008040)
10. No authors listed. Meningococcal disease, serogroup W135, Burkina Faso. Preliminary report, 2002, WUy Epidemiol Record 2002;18:152-5.
11. Nicolas P, Djibo S, Sidikou F, Tenebray B, Stor R. Boisier P. Chanteau S. Epidémies de méningite i méningocoques du groupe X en Afrique en 2006. Med Trop 2006;66:494. (Pubitemid 350203893)
12. Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne X, Mainassara HB et al. Meningococcal meningitis, unprecedented incidence of serogroup X-related cases in 2006 Niger. Clin Infccl Dis 2007;44:657-63.
13. Nicolas P, Norheim G, Gamotel E, Djibo S, Caugant DA. Molecular epidemiology of Neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 show the dominance of the sequence Type (ST-5) and ST-11 complexes. J Clin Microbiol 2005;43:5129-35. (Pubitemid 41484016)
14. Caugant DA, Nicolas P. Molecular surveillance of meningococcal meningitis in Africa. Vaccine 2007;25:A8-11. (Pubitemid 47208590)
15. Lingappa JR. Al-Rabeah AM, Hajjeh R, Mustafa T, Fatani A, Al-Bassam T et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003;9:66-71.
16. Hahné SJ, Gray SJ, Aguilera JF, Crowford NS, Nichols T, Kaczmarski EB, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lane" 2002;359:582-3. (Pubitemid 34178444)
17. Matsika-Claquin MD, Perrocheau A, Taha MK, Levy-Briihl D, Renault P, Alonso JM, et al. Epidémies d'infections à ménincocoque Wl 35 liée au pèlerinage de la Mecque de 2000. Presse Med 2001;30:1529-34. (Pubitemid 33029344)
18. Taha MK, Antignac A, Renault P, Perrocheau A, Levy-Bruhl D, Nicolas P, et al. Expansion clonale de Neisseria meningitidis W115. Presse Med 2001;30:1535-8. (Pubitemid 33029345)
19. Granoff DM. Relative importance of complement-mediated bactericidal and opsonic activity fo protection against meningococcal disease. Vaccine 2009;27:B117-25.
20. Golschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129:1307-26.
21. Pollard AI, Perret KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Epidemiol 2009;9:213-20.
22. Richmond P, Kaczmarski E, Borrow R., Findlow J, Clark S, McCann R et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that in overcome by meningococcal C conjugate vaccine. J Infect Dis 2000;181:761-4. (Pubitemid 30131856)
23. Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum A et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985;2:114-8. (Pubitemid 15046292)
24. Merlin M, Martel G, Debonne JM, Nicolas P, Bailly C, Yazipo D et al. Contrôle d'une épidémie de méningite à méningocoque en Afrique centrale. Santé 1996;6:87-95
25. Balmer P, Borrow, Miller E. Impact of meningococcal C conjugate vaccine in the VK. JMed Microbiol 2002;51:717-22.
26. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27:B112-16.
27. Gotschlich EC, Liu TV, Artenstein MS. Human immunity to the meningococcus 3. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J Exp Med 1969;129:1349-65.
28. Finne J, Leinonen M, Milkela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and, pathogenesis, lancet 1983;2:355-7.
29. Amadou HA, Tohon Z, Djibo S, Moussa A, Zanguina D, Ousmane Serai Etude de l'immunité induite par Neisseria meningitidis de sérogroupe X. Rapport du CERMES (Niamey Niger) 2008.
30. Borrow R, Joseph H, Andrew N, Acuna M, Longworth E, Marin S et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine 2001;19:1129-32.
31. Snape MD, Kelly DF, Lewis S, Banner C, Kibwana L, Moore CE et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008;336:1487-91 (Pubitemid 351977021)
32. Maiden MC, Stuart JM, UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359:1829-31.
33. Maiden MC, Ibarz-Pavôn AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Inject Dit 2008;197:737-43. (Pubitemid 351364476)
34. Hoist J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallagan, et al Properties and clinical performance of vaccines containing outer membrane vesicles from Neissera meningitidis. Vaccine 2009;27:B3-12.
35. Mérieux C. Une aventure des temps modernes: la lute contre l'épidémie de méningite au Brésil. Info Chimie 1976;157:173-7.
36. Guerin PJ, Naess LM, Fogg C, Rosenqvist E, Pinoges L, Bajunirwe F et al. Immunogenicity of fractionnai doses of tetravalent a/c/y/wl35 meningococcal polysaccharide vaccine: results from a randomised non-inferiority controlled trial in Uganda. PLOS Negl Trop Dis 2008;2:e342.
37. Kelly C, Arnold R, Galloway Y, O'Halluhan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007;166:817-23. (Pubitemid 47428901)
38. Prevention and Control of Meningococcal Disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54 No RR-7:1-21
39. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20:S58-67. (Pubitemid 32925012)
40. Meyran M, Desfontaine M, Laroche R. Méningococcies en milieu militaire: émergence du sérogroupe C. Vacination antiméningococcique A+C systématique à l'incorporation. BEH 1992;48:228-9.
41. Marc Laforce F, Ravenscroft N, Djingarey M. Vivianl S. Epidemic meningitis due to groupA Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009;27:B13-19.
42. Van Der Ley P, Poolman JT. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect Immun 1992;60:3156-61.
43. Cartwright K, Morris R, Rumke H, Fox A, Borrow R, Begg N et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999;17:2612-9. (Pubitemid 29314456)
44. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007;31:101-7. (Pubitemid 46058826)
45. Giuliani MM, Adu-Bobie J, Comanducci M, Aricô B, Savino S, Sanlinj Letalk universal vaccine for serogroup B meningococcus. Pwc Natl Acad Sci USA 2006;103:10834-9. (Pubitemid 44148381)
46. Cano R. Larrauri A, Mateo S, Alcau B, Salcedo C, Vazquez JA. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Eum Sim 2004;7:11-5.
47. Vicente D, Esnal O, Lopez De Goicoechea MJ, Cisterna R, Pérez-Trallero E. Influence of two vaccination campaigns on genetic diversity of invasive Neisseria meningitidis isolates in northern Spain (1997-2008). PLoS One 2009;4:e8501.